Noopept (GVS-111)
Dipeptide pro-drug that metabolizes to cyclo-prolylglycine, a compound that upregulates BDNF and NGF expression in the hippocampus and cortex. Modulates AMPA and NMDA receptor subunit expression rather than direct allosteric modulation. Potency is 1000x piracetam by weight, enabling effective doses at 10-30mg. Additional neuroprotective effects via inhibition of calcium-dependent apoptotic cascades.
Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.
- alt
- ast
- homocysteine
- severe-hepatic-impairment
- pregnancy
- lactation
- PMID:19240853Noopept stimulates the expression of NGF and BDNF in rat hippocampus — Bull Exp Biol Med, 2008
- PMID:18577403Neuroprotective action of dipeptide AVP(4-9) analogue — Eksp Klin Farmakol, 2008
- PMID:25065692The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid — J Psychopharmacol, 2014
Noopept is not a racetam. It is a dipeptide that happens to share some downstream effects. The mechanism is upstream of the receptor level. BDNF and NGF upregulation means you are changing the neurotrophic environment, not just tweaking receptor kinetics. 10mg sublingual delivers more than 30mg oral. The Russian clinical literature on this compound runs deep. The Western nootropic community discovered it around 2011 and has been dosing it incorrectly ever since.
This is not medical advice
Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.
See Noopept (GVS-111) in a protocol matched to you